Actinogen Medical Limited (ATGGF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Actinogen Medical Limited (ATGGF) trades at $0.04 with AI Score 53/100 (Grade B). Actinogen Medical Limited is a biotechnology company focused on developing therapies for neurological and neuropsychiatric diseases. Market cap: $149M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ATGGF: ATGGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ATGGF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ATGGF: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Actinogen Medical Limited (ATGGF) Healthcare & Pipeline Overview
Actinogen Medical Limited, an Australian biotechnology firm, specializes in developing therapies for neurological and neuropsychiatric disorders by targeting dysregulated brain cortisol. Their primary asset, Xanamem, an 11ß-HSD1 enzyme inhibitor, is in Phase 2 clinical trials, positioning the company in the competitive Alzheimer's and cognitive impairment treatment landscape.
What Is the Investment Thesis for ATGGF?
Actinogen Medical Limited presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's primary value driver is the successful development and commercialization of Xanamem, its 11ß-HSD1 enzyme inhibitor. Positive Phase 2 clinical trial results could serve as a significant catalyst, potentially leading to partnerships or acquisition offers. The company's focus on neurological and neuropsychiatric diseases addresses a substantial unmet medical need, particularly in Alzheimer's disease and depression with cognitive impairment. However, the company's negative profit margin of -326.3% highlights its reliance on future clinical success and potential funding. Investors should closely monitor Xanamem's clinical trial progress and the company's ability to secure additional financing to sustain operations.
Based on FMP financials and quantitative analysis
ATGGF Key Highlights
Market capitalization of $149M reflects the company's current valuation in the OTC market.
- Gross margin of 96.2% indicates strong potential profitability if Xanamem reaches commercialization.
- Negative P/E ratio of -6.58 due to the company's current lack of profitability.
- Beta of 0.90 suggests the stock is slightly less volatile than the overall market.
- Xanamem is in Phase 2 clinical trials targeting Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome.
Who Are ATGGF's Competitors?
ATGGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BSEM BioStem Technologies, Inc. | $3.35 | +6.19% | $56.8M | — |
| CLTEF Calliditas Therapeutics Ab | $0.18 | -0.39% | $10.8M | 45 |
| HBPCF Helix BioPharma Corp. | $1.71 | +0.00% | $131M | 45 |
| INNMF Amplia Therapeutics Limited | $0.10 | -8.70% | $53.9M | 48 |
| NICXF Nicox S.A. | $0.30 | +0.00% | $29.2M | 55 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATGGF's Key Strengths?
Novel therapeutic approach targeting dysregulated brain cortisol.
- Xanamem is in Phase 2 clinical trials.
- Experienced management team with expertise in drug development.
- Strong intellectual property protection for its technology.
What Are ATGGF's Weaknesses?
Limited financial resources.
- Reliance on the success of Xanamem.
- High risk of clinical trial failure.
- OTC market listing.
What Could Drive ATGGF Stock Higher?
ATGGF catalyst: Announcement of Phase 2 clinical trial results for Xanamem in Alzheimer's disease (estimated timeline: Q4 2026).
- Enrollment of patients in ongoing Phase 2 clinical trials for Xanamem in depression with cognitive impairment.
- Potential for strategic partnerships with larger pharmaceutical companies to fund late-stage development and commercialization.
What Are the Key Risks for ATGGF?
Financial-distress signal — its Altman Z-Score of -20.39 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of Xanamem to demonstrate efficacy in Phase 2 clinical trials.
- Regulatory hurdles and delays in obtaining approval for Xanamem.
- Competition from established pharmaceutical companies developing therapies for similar indications.
- Difficulty securing additional funding to support ongoing research and development activities.
- Risks associated with trading on the OTC market, including limited liquidity and regulatory oversight.
What Are the Growth Opportunities for ATGGF?
- Expansion into New Indications: Actinogen has the opportunity to expand the application of Xanamem beyond its current Phase 2 trials. Exploring its efficacy in other neurological disorders, such as Parkinson's disease or traumatic brain injury, could significantly broaden its market potential. The market for Parkinson's disease treatment alone is projected to reach $5.8 billion by 2028, presenting a substantial growth avenue. This expansion would require further clinical trials and regulatory approvals, potentially extending the timeline by 3-5 years.
- Strategic Partnerships and Licensing Agreements: Partnering with larger pharmaceutical companies for late-stage clinical development and commercialization represents a significant growth opportunity. Such partnerships could provide Actinogen with the financial resources and expertise needed to bring Xanamem to market more effectively. Licensing agreements could generate upfront payments and royalties, providing a steady stream of revenue. The timeline for securing such partnerships is uncertain but could materialize within the next 1-2 years following positive Phase 2 data.
- Advancements in Biomarker Identification: Developing biomarkers to identify patients who are most likely to respond to Xanamem could enhance its clinical trial success rates and improve its market positioning. Biomarker-driven patient selection can lead to more targeted and effective treatment, increasing the likelihood of regulatory approval and commercial adoption. The timeline for biomarker development is estimated at 2-3 years, requiring significant investment in research and development.
- Geographic Expansion: Expanding clinical trials and eventual commercialization efforts beyond Australia could unlock significant growth potential. Targeting markets in North America and Europe, where there is a high prevalence of Alzheimer's disease and depression, could substantially increase Xanamem's revenue potential. This expansion would require navigating different regulatory landscapes and establishing distribution networks, potentially taking 3-5 years to fully implement.
- Development of Next-Generation 11ß-HSD1 Inhibitors: Investing in the development of next-generation 11ß-HSD1 inhibitors with improved efficacy and safety profiles could provide a long-term competitive advantage. These new compounds could address limitations of Xanamem and expand the company's pipeline. The timeline for developing and testing new compounds is typically 5-7 years, requiring sustained investment in research and development.
What Are ATGGF's Competitive Advantages?
- Patented 11ß-HSD1 enzyme inhibitor technology.
- Clinical trial data demonstrating efficacy in target indications.
- Expertise in developing therapies for dysregulated brain cortisol.
- Established relationships with key opinion leaders in the field.
What Does ATGGF Do?
Actinogen Medical Limited, founded in 1999 and based in Sydney, Australia, is a biotechnology company dedicated to developing innovative therapies for neurological and neuropsychiatric diseases. The company focuses on addressing conditions linked to dysregulated brain cortisol, a key factor in various cognitive and mood disorders. Their lead product, Xanamem, is an inhibitor of the 11ß-HSD1 enzyme, which plays a crucial role in regulating cortisol levels within the brain. Xanamem is currently undergoing Phase 2 clinical trials, targeting Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems associated with fragile X syndrome. Originally incorporated as Actinogen Limited, the company rebranded as Actinogen Medical Limited in November 2015, reflecting its sharpened focus on medical applications. Actinogen's research and development efforts are centered in Australia, with the company seeking to expand its reach through strategic partnerships and collaborations. The company's approach involves modulating cortisol levels in the brain to improve cognitive function and alleviate symptoms associated with neurological and neuropsychiatric disorders. By targeting a specific enzyme, Actinogen aims to provide a more targeted and effective treatment option compared to traditional therapies.
What Products and Services Does ATGGF Offer?
- Develop therapies for neurological diseases.
- Develop therapies for neuropsychiatric diseases.
- Focus on diseases associated with dysregulated brain cortisol.
- Develop Xanamem, an inhibitor of the 11ß-HSD1 enzyme.
- Conduct Phase 2 clinical trials for Xanamem.
- Target Alzheimer's disease with Xanamem.
- Target depression with cognitive impairment with Xanamem.
- Target anxiety, sleep, and behavioral problems in fragile X syndrome with Xanamem.
How Does ATGGF Make Money?
- Develops and patents novel therapeutic compounds.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from health authorities.
- Out-licenses or partners with pharmaceutical companies for commercialization.
What Industry Does ATGGF Operate In?
Actinogen Medical Limited operates within the competitive biotechnology industry, focusing on neurological and neuropsychiatric disorders. The market for Alzheimer's disease and depression treatments is substantial and growing, driven by an aging population and increasing awareness of mental health issues. Key trends in the industry include the development of targeted therapies, such as enzyme inhibitors, and the use of biomarkers to identify patients who are most likely to respond to treatment. Actinogen competes with larger pharmaceutical companies and other biotechnology firms developing therapies for similar indications. The company's success depends on its ability to demonstrate the safety and efficacy of Xanamem in clinical trials and secure regulatory approval.
Who Are ATGGF's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel therapies.
- Patients suffering from neurological and neuropsychiatric diseases.
- Healthcare providers prescribing treatments for these conditions.
- Research institutions collaborating on clinical trials.
Actinogen Medical Limited (ATGGF) Valuation Context
Valued at $149M, ATGGF is classified as a micro-cap stock. Relative to its peer group, ATGGF's quantitative score of 53/100 is roughly in line with the peer average of 48/100.
ATGGF Revenue & Earnings Trend
In Q2 2025, ATGGF generated $5.5M in top-line revenue, marking a sequential decrease of 39.2%. The company recorded a net loss of $6.6M, with diluted EPS of $-0.00.
Company Profile
Actinogen Medical Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sydney, AU. The company is led by CEO Steven G. Gourlay. ATGGF has traded publicly since 2018.
Key Financial Metrics
Its free cash flow yield is -12.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Actinogen Medical Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.39 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Actinogen Medical Limited revenue of about $7.6M for fiscal 2026, with EPS near $-0.00.
ATGGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel therapeutic approach targeting dysregulated brain cortisol.
- Xanamem is in Phase 2 clinical trials.
- Experienced management team with expertise in drug development.
- Strong intellectual property protection for its technology.
Bear Case
- Limited financial resources.
- Reliance on the success of Xanamem.
- High risk of clinical trial failure.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $5M | -$7M | -$0.0022 |
| Q2 2024 | $9M | -$1M | -$0.0007 |
Based on FMP financials and quantitative analysis
ATGGF Latest News
No recent news available for ATGGF.
ATGGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATGGF.
Price Targets
Wall Street price target analysis for ATGGF.
ATGGF MoonshotScore
What does this score mean?
The MoonshotScore rates ATGGF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Steven G. Gourlay
CEO
Steven G. Gourlay brings extensive experience in the pharmaceutical and biotechnology industries to his role as CEO of Actinogen Medical Limited. His career spans various leadership positions in drug development, clinical research, and commercialization. He has a proven track record of guiding companies through critical stages of growth and development. Gourlay's expertise encompasses strategic planning, financial management, and investor relations, making him well-suited to lead Actinogen through its clinical trial programs and potential commercialization efforts.
Track Record: Under Steven G. Gourlay's leadership, Actinogen Medical Limited has focused on advancing the clinical development of Xanamem, its lead drug candidate. Key milestones include the initiation and progression of Phase 2 clinical trials in Alzheimer's disease and other neurological disorders. Gourlay has also overseen efforts to secure funding and establish partnerships to support the company's research and development activities. His strategic decisions have been instrumental in positioning Actinogen within the competitive biotechnology landscape.
ATGGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Actinogen Medical Limited may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited regulatory oversight and may not be required to file regular financial reports with the SEC. This lack of transparency can increase the risk for investors, as there may be less information available to assess the company's financial health and operations. Investing in companies on the OTC Other tier requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Potential for price manipulation and fraud.
- Higher bid-ask spreads and lower trading volume.
- Difficulty obtaining accurate and timely information.
- Increased risk of delisting or suspension of trading.
- Verify the company's registration and licensing status.
- Review the company's financial statements, if available.
- Assess the company's management team and their track record.
- Research the company's products or services and their market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company is actively developing a drug in Phase 2 clinical trials.
- Company has patents protecting its core technology.
- Company has a scientific advisory board with recognized experts.
- Company has a CEO with relevant industry experience.
Actinogen Medical Limited Healthcare Stock: Key Questions Answered
What does the AI Score mean for ATGGF?
ATGGF holds an AI Score of 53/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Actinogen Medical Limited is a biotechnology company focused on developing therapies for neurological and neuropsychiatric diseases. Their lead drug candidate, Xanamem, is currently in Phase 2 …
What does Actinogen Medical Limited do?
Actinogen Medical Limited is a biotechnology company focused on developing therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. Their lead drug candidate, Xanamem, is an inhibitor of the 11ß-HSD1 enzyme, which is currently in Phase 2 clinical trials.
What do analysts say about ATGGF stock?
As of 2026-03-17, there is no readily available analyst consensus on Actinogen Medical Limited (ATGGF) due to its OTC listing and relatively small market capitalization. Investors should conduct their own thorough due diligence, considering the company's clinical trial progress, financial position, and competitive landscape.
What are the main risks for ATGGF?
The main risks for Actinogen Medical Limited include the inherent uncertainties of clinical drug development, particularly the risk of Xanamem failing to demonstrate efficacy or safety in Phase 2 or later trials. Regulatory hurdles and potential delays in obtaining approval from health authorities also pose significant risks. Furthermore, the company faces competition from larger pharmaceutical companies with greater resources.
What are the key factors to evaluate for ATGGF?
Actinogen Medical Limited (ATGGF) holds an AI score of 53/100 (moderate). Actinogen Medical Limited presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does ATGGF data refresh on this page?
ATGGF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ATGGF's recent stock price performance?
Actinogen Medical Limited (ATGGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapeutic approach targeting dysregulated brain cortisol. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATGGF overvalued or undervalued right now?
Actinogen Medical Limited (ATGGF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ATGGF before investing?
Before investing in Actinogen Medical Limited (ATGGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- Clinical trial outcomes are inherently uncertain.